Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
The baseline analysis was conducted on the basis that no small HCC were detected incidentally in the no-surveillance group, the annual incidence of HCC was 4%, and transplantation was not selected for ...
Outcomes including local recurrence, distant metastases, and survival as well as toxicity data were modeled by a patient-level Markov microsimulation model, which were validated against trial data.
The fitted Weibull survival curves are shown in Figure 2. Median survival was projected to be 55 months with imatinib mesylate treatment and 20 months without imatinib mesylate. Estimated mean life ...
Expensive therapies—even those with record high prices—may offer substantial health gains and thus have comparable value, in terms of cost-effectiveness, to less expensive conventional treatments. To ...
Introduction Prior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback